- Home
- PRAX vs KRC Comparison
PRAX vs KRC Comparison
Compare PRAX & KRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- KRC
- Stock Information
- Founded
- PRAX 2015
- KRC 1947
- Country
- PRAX United States
- KRC United States
- Employees
- PRAX N/A
- KRC N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- KRC Real Estate Investment Trusts
- Sector
- PRAX Health Care
- KRC Real Estate
- Exchange
- PRAX Nasdaq
- KRC Nasdaq
- Market Cap
- PRAX 4.0B
- KRC 4.8B
- IPO Year
- PRAX 2020
- KRC 1997
- Fundamental
- Price
- PRAX $178.75
- KRC $40.68
- Analyst Decision
- PRAX Strong Buy
- KRC Hold
- Analyst Count
- PRAX 13
- KRC 12
- Target Price
- PRAX $202.85
- KRC $40.25
- AVG Volume (30 Days)
- PRAX 1.4M
- KRC 1.4M
- Earning Date
- PRAX 11-07-2025
- KRC 10-27-2025
- Dividend Yield
- PRAX N/A
- KRC 5.31%
- EPS Growth
- PRAX N/A
- KRC 9.52
- EPS
- PRAX N/A
- KRC 1.84
- Revenue
- PRAX $7,765,000.00
- KRC $1,137,053,000.00
- Revenue This Year
- PRAX N/A
- KRC N/A
- Revenue Next Year
- PRAX $20.00
- KRC $5.73
- P/E Ratio
- PRAX N/A
- KRC $22.10
- Revenue Growth
- PRAX 338.45
- KRC 2.26
- 52 Week Low
- PRAX $26.70
- KRC $27.07
- 52 Week High
- PRAX $205.89
- KRC $45.03
- Technical
- Relative Strength Index (RSI)
- PRAX 80.27
- KRC 43.83
- Support Level
- PRAX $164.75
- KRC $39.74
- Resistance Level
- PRAX $192.96
- KRC $41.40
- Average True Range (ATR)
- PRAX 11.99
- KRC 0.94
- MACD
- PRAX 13.57
- KRC -0.07
- Stochastic Oscillator
- PRAX 82.53
- KRC 37.02
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.